Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000899923-23-000035
Filing Date
2023-05-04
Accepted
2023-05-04 16:12:46
Documents
87
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mygn-20230331.htm   iXBRL 10-Q 1187450
2 EX-10.1 restrictedstockunitagreeme.htm EX-10.1 47628
3 EX-31.1 exhibit311-certificationof.htm EX-31.1 10538
4 EX-31.2 exhibit312-certificationof.htm EX-31.2 10539
5 EX-32.1 exhibit321-certificationpu.htm EX-32.1 6200
  Complete submission text file 0000899923-23-000035.txt   6715045

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20230331.xsd EX-101.SCH 44271
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mygn-20230331_cal.xml EX-101.CAL 82799
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20230331_def.xml EX-101.DEF 200954
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20230331_lab.xml EX-101.LAB 582837
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20230331_pre.xml EX-101.PRE 381316
81 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20230331_htm.xml XML 1137060
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-26642 | Film No.: 23888857
SIC: 2835 In Vitro & In Vivo Diagnostic Substances